ClinicalTrials.gg
CompletedNCT02468674Updated Jun 16, 2020Results posted

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

A Phase 2 interventional study of bimagrumab and Placebo in Sarcopenia, sponsored by Novartis Pharmaceuticals. Completed at 30 sites in 12 countries. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Study summary

This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.

Read the detailed description

Two populations were defined as below:

  • Population I: Patients enrolled prior to the protocol amendment 1, who received bimagrumab 70 mg, 210 mg or 700 mg in the core study, were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Patients receiving placebo in the core study continued receiving placebo in the extension study.
  • Population II: Patients enrolled after protocol amendment 1, who received bimagrumab 700 mg or placebo in the core study, did not receive study medication in the extension study and were followed-up per schedule defined in this protocol amendment.
02

Conditions studied

  • Sarcopenia

Keywords

  • Sarcopenia, muscle wasting, elderly, strength, physical function, lean body mass, gait speed
03

In context

Sarcopenia

1,330 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

This study's enrollment of 160 is above the median of 60 across 855 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 70 years or older that have participated in, and have completed the full study treatment period per protocol (24 weeks/EOT visit) in the preceding core study (CBYM338E2202)

Exclusion criteria

Exclusion criterion:

  • Any condition which should have led to treatment discontinuation per protocol in the core study (CBYM338E2202)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Other
    Follow-up (arm 1)

    Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.

    Drug: bimagrumab · Drug: Placebo

  • No intervention
    Follow-up (arm 2)

    Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.

Interventions

  • bimagrumab low dose bimagrumab moderate dose bimagrumab high dose Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.

  • DrugPlacebo

    Placebo Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.

06

What researchers measure

Primary outcomes

  1. Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49

    SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).

    Time frame: Week 49

  2. Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49

    SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).

    Time frame: Week 49

Secondary outcomes

  1. Population I: 6-minute Walking Distance (6MWT) at Week 49

    The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.

    Time frame: Week 49

  2. Population II: 6-minute Walking Distance (6MWT) at Week 49

    The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.

    Time frame: Week 49

  3. Population I: Gait Speed at Week 49

    Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.

    Time frame: Week 49

  4. Population II: Gait Speed at Week 49

    Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.

    Time frame: Week 49

  5. Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

    ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.

    Time frame: Week 49

  6. Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

    ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.

    Time frame: Week 49

  7. Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

    LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect

    Time frame: Week 49

  8. Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

    LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect

    Time frame: Week 49

07

Results

Posted Dec 9, 2019

Participant flow

This study was conducted in 30 centers in 12 countries: Australia (1), Belgium (1), Czech Republic (1), Denmark (1), France (2), Japan (10), Russia (4), South Korea (1), Spain (2), Switzerland (1), Taiwan (1), United States (5).

Participant flow — Overall Study
MilestonePopulation I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II Placebo
Started555477156943
Completed455366146540
Not completed100111143
Withdrew: Adverse event000101000
Withdrew: Lost to follow-up100000011
Withdrew: Physician decision000000100
Withdrew: Patient/guardian decision000010021
Withdrew: Protocol deviation000000011

Outcome measures

PrimaryPopulation I: Short Physical Performance Battery (SPPB) Total Score at Week 49

SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).

Time frame:
Week 49
Reported as:
Mean · Scores on a scale
Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49
Scores on a scalePopulation I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: Placebo
Population I: Short Physical Performance Battery (SPPB) Total Score at Week 498.8 ± 3.8610.2 ± 1.928.0 ± 2.358.0 ± 2.659.5 ± 2.177.5 ± 3.789.6 ± 1.83
Statistical analysis
  • Population I: BYM338 700 mg vs Population I BYM338: 700 mg to Placebo · t-test, 1 sided · p = 0.759One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I BYM338: 210 mg to Placebo · t-test, 1 sided · p = 0.500One-sided test at the 0.025 significance level.
  • Population I: BYM338 70 mg vs Population I: BYM338 70 mg to Placebo · t-test, 1 sided · p = 0.144One-sided test at the 0.025 significance
  • Population I: BYM338 700 mg vs Population I: Placebo · t-test, 1 sided · p = 0.648One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I: Placebo · t-test, 1 sided · p = 0.929One-sided test at the 0.025 significance
  • Population I: BYM338 70 mg vs Population I: Placebo · t-test, 1 sided · p = 0.530One-sided test at the 0.025 significance
PrimaryPopulation II: Short Physical Performance Battery (SPPB) Total Score at Week 49

SPPB evaluates lower extremities in three functional components: maintenance of standing balance, usual gait speed and chair stand. Each test yields a score on a scale from 0 to 4 (total score 0-12, with the higher score reflecting a higher level of function).

Time frame:
Week 49
Reported as:
Mean · Scores on a scale
Population II: Short Physical Performance Battery (SPPB) Total Score at Week 49
Scores on a scalePopulation: II BYM338 700 mgPopulation: II Placebo
Population II: Short Physical Performance Battery (SPPB) Total Score at Week 498.6 ± 2.408.8 ± 1.55
Statistical analysis
  • Population: II BYM338 700 mg vs Population: II Placebo · ANCOVA · p = 0.839Difference in the least square means (SE)
SecondaryPopulation I: 6-minute Walking Distance (6MWT) at Week 49

The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.

Time frame:
Week 49
Reported as:
Mean · meters
Population I: 6-minute Walking Distance (6MWT) at Week 49
metersPopulation I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: Placebo
Population I: 6-minute Walking Distance (6MWT) at Week 49318.2 ± 159.55354.1 ± 69.98304.1 ± 63.05361.5 ± 144.53316.1 ± 97.87273.4 ± 154.03368.7 ± 108.37
Statistical analysis
  • Population I: BYM338 700 mg vs Population I BYM338: 700 mg to Placebo · t-test, 1 sided · p = 0.669One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I BYM338: 210 mg to Placebo · t-test, 1 sided · p = 0.773One-sided test at the 0.025 significance level.
  • Population I: BYM338 70 mg vs Population I: BYM338 70 mg to Placebo · t-test, 1 sided · p = 0.290One-sided test at the 0.025 significance level.
  • Population I: BYM338 700 mg vs Population I: Placebo · t-test, 1 sided · p = 0.766One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I: Placebo · t-test, 1 sided · p = 0.885One-sided test at the 0.025 significance level.
  • Population I: BYM338 70 mg vs Population I: Placebo · t-test, 1 sided · p = 0.840One-sided test at the 0.025 significance level.
SecondaryPopulation II: 6-minute Walking Distance (6MWT) at Week 49

The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. A high 6MWT represent better physical condition.

Time frame:
Week 49
Reported as:
Mean · meters
Population II: 6-minute Walking Distance (6MWT) at Week 49
metersPopulation: II BYM338 700 mgPopulation: II Placebo
Population II: 6-minute Walking Distance (6MWT) at Week 49321.2 ± 105.13323.1 ± 96.47
Statistical analysis
  • Population: II BYM338 700 mg vs Population: II Placebo · ANCOVA · p = 0.367Difference in the least square means (SE)
SecondaryPopulation I: Gait Speed at Week 49

Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.

Time frame:
Week 49
Reported as:
Mean · m/sec
Population I: Gait Speed at Week 49
m/secPopulation I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: Placebo
Population I: Gait Speed at Week 490.8 ± 0.351.0 ± 0.180.9 ± 0.171.1 ± 0.240.9 ± 0.150.7 ± 0.350.8 ± 0.18
Statistical analysis
  • Population I: BYM338 700 mg vs Population I BYM338: 700 mg to Placebo · t-test, 1 sided · p = 0.875One-sided test at the 0.025 significance
  • Population I: BYM338 210 mg vs Population I BYM338: 210 mg to Placebo · t-test, 1 sided · p = 0.909One-sided test at the 0.025 significance
  • Population I: BYM338 70 mg vs Population I: BYM338 70 mg to Placebo · t-test, 1 sided · p = 0.168One-sided test at the 0.025 significance
  • Population I: BYM338 700 mg vs Population I: Placebo · t-test, 1 sided · p = 0.632One-sided test at the 0.025 significance
  • Population I: BYM338 210 mg vs Population I: Placebo · t-test, 1 sided · p = 0.310One-sided test at the 0.025 significance
  • Population I: BYM338 70 mg vs Population I: Placebo · t-test, 1 sided · p = 0.321One-sided test at the 0.025 significance
SecondaryPopulation II: Gait Speed at Week 49

Gait Speed was assessed as part of SPPB, over a 4 meter distance of a 6 meter course. Gait speed assesses a person's usual walking speed, which is defined as the speed a person normally walks from one place to another. Poor functional performance is measured by slow or declining gait speed.

Time frame:
Week 49
Reported as:
Mean · m/sec
Population II: Gait Speed at Week 49
m/secPopulation: II BYM338 700 mgPopulation: II Placebo
Population II: Gait Speed at Week 490.9 ± 0.240.9 ± 0.17
Statistical analysis
  • Population: II BYM338 700 mg vs Population: II Placebo · ANCOVA · p = 0.395Difference in the least square means (SE)
SecondaryPopulation I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.

Time frame:
Week 49
Reported as:
Geometric mean · kg/m^2
Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
kg/m^2Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: Placebo
Population I: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 496.6 ± 7.226.0 ± 14.056.1 ± 8.085.8 ± 15.085.9 ± 14.195.2 ± 14.855.6 ± 15.21
Statistical analysis
  • Population I: BYM338 700 mg vs Population I BYM338: 700 mg to Placebo · t-test, 1 sided · p = 0.120One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I BYM338: 210 mg to Placebo · t-test, 1 sided · p = 0.297One-sided test at the 0.025 significance level.
  • Population I: BYM338 70 mg vs Population I: BYM338 70 mg to Placebo · t-test, 1 sided · p = 0.074One-sided test at the 0.025 significance level.
  • Population I: BYM338 700 mg vs Population I: Placebo · t-test, 1 sided · p = 0.022One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I: Placebo · t-test, 1 sided · p = 0.106One-sided test at the 0.025 significance level.
  • Population I: BYM338 70 mg vs Population I: Placebo · t-test, 1 sided · p = 0.211One-sided test at the 0.025 significance level.
SecondaryPopulation II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

ASMI is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.

Time frame:
Week 49
Reported as:
Geometric mean · kg/m^2
Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
kg/m^2Population: II BYM338 700 mgPopulation: II Placebo
Population II: Appendicular Skeletal Muscle Index (ASMI) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 495.6 ± 14.365.5 ± 12.46
Statistical analysis
  • Population: II BYM338 700 mg vs Population: II Placebo · ANCOVA · p = 1.000Difference in the least square geometric means
SecondaryPopulation I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect

Time frame:
Week 49
Reported as:
Geometric mean · kg
Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
kgPopulation I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: Placebo
Population I: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 4941.4 ± 21.1134.0 ± 17.7635.5 ± 15.3932.6 ± 25.2334.9 ± 21.1634.0 ± 18.4732.6 ± 17.95
Statistical analysis
  • Population I: BYM338 700 mg vs Population I BYM338: 700 mg to Placebo · t-test, 1 sided · p = 0.084One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I BYM338: 210 mg to Placebo · t-test, 1 sided · p = 0.283One-sided test at the 0.025 significance level.
  • Population I: BYM338 70 mg vs Population I: BYM338 70 mg to Placebo · t-test, 1 sided · p = 0.323One-sided test at the 0.025 significance level.
  • Population I: BYM338 700 mg vs Population I: Placebo · t-test, 1 sided · p = 0.018One-sided test at the 0.025 significance level.
  • Population I: BYM338 210 mg vs Population I: Placebo · t-test, 1 sided · p = 0.179One-sided test at the 0.025 significance level.
  • Population I: BYM338 70 mg vs Population I: Placebo · t-test, 1 sided · p = 0.227One-sided test at the 0.025 significance level.
SecondaryPopulation II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49

LBM is defined as the Total soft tissue fat-free body mass. A high LBM represents better pharmacodynamic effect

Time frame:
Week 49
Reported as:
Geometric mean · kg
Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 49
kgPopulation: II BYM338 700 mgPopulation: II Placebo
Population II: Total Lean Body Mass (LBM) as Measured by Dual Energy X-ray Absorptiometry (DXA) at Week 4934.9 ± 25.0133.7 ± 20.40
Statistical analysis
  • Population: II BYM338 700 mg vs Population: II Placebo · ANCOVA · p = 1.000Difference in the least square geometric means

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum treatment duration of 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Population I BYM338 700 mg0/5 (0%)0/5 (0%)4/5 (80%)
Population I BYM338 700 mg to Placebo0/5 (0%)1/5 (20%)4/5 (80%)
Population I BYM338 210 mg0/5 (0%)0/5 (0%)3/5 (60%)
Population I BYM338 210 mg to Placebo0/4 (0%)0/4 (0%)2/4 (50%)
Population I BYM338 70 mg0/7 (0%)0/7 (0%)5/7 (71.4%)
Population I BYM338 70 mg to Placebo0/7 (0%)2/7 (28.6%)3/7 (42.9%)
Population I Placebo0/15 (0%)2/15 (13.3%)11/15 (73.3%)
Population: II BYM338 700 mg0/69 (0%)0/69 (0%)0/69 (0%)
Population: II Placebo0/43 (0%)0/43 (0%)0/43 (0%)
Most frequent serious events
Most frequent serious events
EventPopulation I BYM338 700 mgPopulation I BYM338 700 mg to PlaceboPopulation I BYM338 210 mgPopulation I BYM338 210 mg to PlaceboPopulation I BYM338 70 mgPopulation I BYM338 70 mg to PlaceboPopulation I PlaceboPopulation: II BYM338 700 mgPopulation: II Placebo
SeizureNervous system disorders0/51/50/50/40/70/70/150/690/43
FallInjury, poisoning and procedural complications0/50/50/50/40/71/70/150/690/43
Lumbar vertebral fractureInjury, poisoning and procedural complications0/50/50/50/40/71/70/150/690/43
OsteoarthritisMusculoskeletal and connective tissue disorders0/50/50/50/40/71/70/150/690/43
Gallbladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/50/50/40/71/70/150/690/43
CataractEye disorders0/50/50/50/40/70/71/150/690/43
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/50/50/40/70/71/150/690/43
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPopulation I BYM338 700 mgPopulation I BYM338 700 mg to PlaceboPopulation I BYM338 210 mgPopulation I BYM338 210 mg to PlaceboPopulation I BYM338 70 mgPopulation I BYM338 70 mg to PlaceboPopulation I PlaceboPopulation: II BYM338 700 mgPopulation: II Placebo
FallInjury, poisoning and procedural complications1/51/50/51/42/70/76/150/690/43
Herpes zosterInfections and infestations0/50/50/50/42/70/71/150/690/43
Back painMusculoskeletal and connective tissue disorders1/50/50/50/42/71/70/150/690/43
Ventricular extrasystolesCardiac disorders0/50/50/51/40/70/70/150/690/43
GastroenteritisInfections and infestations0/50/50/51/40/70/70/150/690/43
Skin abrasionInjury, poisoning and procedural complications0/50/50/51/40/70/70/150/690/43
Prostatic dysplasiaReproductive system and breast disorders0/50/50/51/40/70/70/150/690/43
Dry eyeEye disorders0/50/51/50/40/70/70/150/690/43
Chronic gastritisGastrointestinal disorders1/50/50/50/40/70/70/150/690/43
Large intestine polypGastrointestinal disorders1/50/50/50/40/70/70/150/690/43

Baseline characteristics

160 participants were enrolled into the study: 48 in Population I (patients enrolled prior to protocol amendment 1) and 112 in Population II (patients enrolled after protocol amendment 1)

Age, Continuous
Age, Continuous(Years)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Mean80.0 ± 4.9079.4 ± 7.2779.0 ± 1.5874.8 ± 2.6377.6 ± 6.7581.6 ± 4.5879.9 ± 4.22——79.2 ± 4.91
Age, Continuous
Age, Continuous(Years)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Mean———————79.8 ± 5.0578.2 ± 5.2979.2 ± 5.18
Sex: Female, Male
Sex: Female, Male(Participants)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Female12223580023
Male43324270025
Sex: Female, Male
Sex: Female, Male(Participants)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Female0000000402969
Male0000000291443
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Asian1001226——12
Black0000111——3
Caucasian4553448——33
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Asian———————11314
Caucasian———————564096
Native American———————101
Pacific Islander———————101
Population I: Short Physical Performance Battery (SPPB) total score at Week 25
Population I: Short Physical Performance Battery (SPPB) total score at Week 25(Scores on a scale)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Mean8.8 ± 2.1710.4 ± 1.348.6 ± 1.678.5 ± 1.918.9 ± 2.048.0 ± 3.279.1 ± 1.58——8.9 ± 2.01
Population II: Short Physical Performance Battery (SPPB) total score at Week 25
Population II: Short Physical Performance Battery (SPPB) total score at Week 25(Scores on a scale)Population I: BYM338 700 mgPopulation I BYM338: 700 mg to PlaceboPopulation I: BYM338 210 mgPopulation I BYM338: 210 mg to PlaceboPopulation I: BYM338 70 mgPopulation I: BYM338 70 mg to PlaceboPopulation I: PlaceboPopulation: II BYM338 700 mgPopulation: II PlaceboTotal
Mean———————8.5 ± 2.178.2 ± 2.258.4 ± 2.20

4 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Novartis Investigative Site
    Miami Lakes, Florida 33014, United States
  • Novartis Investigative Site
    Gainesville, Georgia 30501, United States
  • Novartis Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Madison, Wisconsin 53705, United States
  • Novartis Investigative Site
    St Albans, Victoria 3021, Australia
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Praha 2, 12000, Czechia
  • Novartis Investigative Site
    Copenhagen NV, 2400, Denmark
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Obu-city, Aichi 474-8511, Japan
  • Novartis Investigative Site
    Toyohashi-city, Aichi 440-8510, Japan
  • Novartis Investigative Site
    Mizunami-city, Gifu 509 6134, Japan
  • Novartis Investigative Site
    Nara-city, Nara 630-8581, Japan
  • Novartis Investigative Site
    Kawachinagano, Osaka 586-8521, Japan
  • Novartis Investigative Site
    Kitaadachigun Inamachi, Saitama 362-0806, Japan
  • Novartis Investigative Site
    Kitamoto-city, Saitama 364-8501, Japan
  • Novartis Investigative Site
    Itabashi ku, Tokyo 173 0015, Japan
  • Novartis Investigative Site
    Kiyose-city, Tokyo 204-0021, Japan
  • Novartis Investigative Site
    Koto-ku, Tokyo 136-0075, Japan
  • Novartis Investigative Site
    Suwon si, Gyeonggi Do 16499, Korea, Republic of
  • Novartis Investigative Site
    Moscow, 101990, Russian Federation
  • Novartis Investigative Site
    Moscow, 117997, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 190068, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150003, Russian Federation
  • Novartis Investigative Site
    Albacete, Castilla La Mancha 02006, Spain
  • Novartis Investigative Site
    Getafe, Madrid 28905, Spain
  • Novartis Investigative Site
    Genève 14, 1211, Switzerland
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Dec 2018, 40 months.

Results were first posted in Dec 2019, 1 year after primary completion.

Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2015
First posted
Jun 11, 2015
StartActual
Jul 22, 2015
Primary completionActual
Dec 3, 2018
CompletionActual
Dec 3, 2018
Results first posted
Dec 9, 2019
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02468674
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Jul 22, 2015
Primary completion
Dec 3, 2018
Completion
Dec 3, 2018
Results posted
Dec 9, 2019
Last update
Jun 16, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion